← FDA DRUG APPROVALS

FDA ANDA · ANDA200463

ITRACONAZOLE

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA200463
TYPE
ANDA
ORIGINAL APPROVAL
2012-07-20
LATEST ACTION
2019-10-11
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

ITRACONAZOLEDiscontinued
ITRACONAZOLE 100MG · CAPSULE · ORAL

Approval history

2019-10-11Labeling · Supplement 7 · standardAP
2019-10-11Labeling · Supplement 5 · standardAP
2019-10-11Labeling · Supplement 8 · standardAP
2019-10-11Labeling · Supplement 6 · standardAP
2016-05-16Labeling · Supplement 1 · standardAP
2016-05-16Labeling · Supplement 2 · standardAP
2012-07-20Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →